Correction to 'Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity'.

Gayle, Sophia; Aiello, Robert; Leelatian, Nalin; Beckta, Jason M; Bechtold, Jane; Bourassa, Patricia; Csengery, Johanna; Maguire, Robert J; Marshall, Dan; Sundaram, Ranjini K; Van Doorn, Jinny; Jones, Kelli; Moore, Hunter; Lopresti-Morrow, Lori; Paradis, Timothy; Tylaska, Laurie; Zhang, Qing; Visca, Hannah; Reshetnyak, Yana K; Andreev, Oleg A; Engelman, Donald M; Glazer, Peter M; Bindra, Ranjit S; Paralkar, Vishwas M

Gayle, Sophia; Aiello, Robert; Leelatian, Nalin; Beckta, Jason M; Bechtold, Jane; Bourassa, Patricia; Csengery, Johanna; Maguire, Robert J; Marshall, Dan; Sundaram, Ranjini K; Van Doorn, Jinny; Jones, Kelli; Moore, Hunter; Lopresti-Morrow, Lori; Paradis, Timothy; Tylaska, Laurie; Zhang, Qing; Visca, Hannah; Reshetnyak, Yana K; Andreev, Oleg A; Engelman, Donald M; Glazer, Peter M; Bindra, Ranjit S; Paralkar, Vishwas M.

Affiliation

Gayle S; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Aiello R; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Leelatian N; Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Beckta JM; Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Bechtold J; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Bourassa P; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Csengery J; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Maguire RJ; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Marshall D; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Sundaram RK; Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Van Doorn J; Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Jones K; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Moore H; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Lopresti-Morrow L; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Paradis T; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Tylaska L; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Zhang Q; Cybrexa Therapeutics, New Haven, CT 06511, USA.
Visca H; Physics Department, University of Rhode Island, Kingston, RI 02881, USA.
Reshetnyak YK; Physics Department, University of Rhode Island, Kingston, RI 02881, USA.
Andreev OA; Physics Department, University of Rhode Island, Kingston, RI 02881, USA.
Engelman DM; Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, CT 06511, USA.
Glazer PM; Department of Therapeutic Radiology, Yale University School of Medicine, New Haven, CT 06520, USA.
Bindra RS; Department of Pathology, Yale University School of Medicine, New Haven, CT 06520, USA.
Paralkar VM; Cybrexa Therapeutics, New Haven, CT 06511, USA.

NAR Cancer ; 3(4): zcab047, 2021 Dec.

Article de En | MEDLINE | ID: mdl-34888524

ABSTRACT

ABSTRACT

[This corrects the article DOI 10.1093/narcan/zcab021.].

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Diagnostic_studies Langue: En Journal: NAR Cancer Année: 2021 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google